Pfizer To Spend 2016 Playing Catch Up In Big Therapeutic Categories
This article was originally published in The Pink Sheet Daily
The big pharma reported the first positive Phase III data for its PCSK9 inhibitor bococizumab and confirmed it is on track to file the SGLT2 inhibitor ertugliflozin in the US this year, but both drugs will compete in markets already crowded with rivals. The same is true for its PD-L1 inhibitor avelumab.
You may also be interested in...
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.
The company showcased its expanded cancer drug pipeline two months after completing the acquisition of Seagen last year.